Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Benitec Biopharma Inc.NASDAQ: BNTC
Net Receivables · Q3 FY2026 · quarter ended Mar 2026
Net receivables broadly unchanged from a year ago
Net receivables stood at $3K at the end of Q3 FY2026, up 0.0% from a year earlier and down 97.7% from the prior quarter. Over 3 fiscal years it compounded at +122.4% a year.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 33K USD
- Year-over-year change
- -85.6%
- 4-year CAGR
- +7.2%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 33K | -85.6% |
| FY2024 | 2024-06-30 | 229K | +316.4% |
| FY2023 | 2023-06-30 | 55K | +1733.3% |
| FY2022 | 2022-06-30 | 3K | -88.0% |
| FY2021 | 2021-06-30 | 25K | — |
Net Receivables vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 net receivables of $3K is the 6th highest of the 10 companies compared; the peer median is $203K.
- Its year-over-year change of +0.0% is the 4th highest of 7, against a peer median of -4.4%.
- Net receivables amounts to 0.0% of total assets for BNTC, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $86.26M | +502.5% | +37.8% | 16.4% | |
| Mar 2026 | $23.32M | +28.1% | +27.4% | 8.6% | |
| Dec 2025 | $8.13M | -37.0% | -28.6% | 1.5% | |
| Mar 2026 | $806K | +278.4% | +73.9% | 0.7% | |
| Mar 2026 | $203K | -80.3% | — | 0.1% | |
| Mar 2026 | $3K | +0.0% | +122.4% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BNTC) | $203K | -4.4% | +32.6% | 0.1% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.